Plant-derived compounds for treating autosomal dominant polycystic kidney disease

Jieting Zhang; Jiaxin Chen; Jing Xu; Cheng Xue; Zhiguo Mao

doi:10.3389/fneph.2023.1071441

Plant-derived compounds for treating autosomal dominant polycystic kidney disease

Front Nephrol. 2023 Feb 3:3:1071441. doi: 10.3389/fneph.2023.1071441. eCollection 2023.

Authors

Jieting Zhang^{1

2}, Jiaxin Chen², Jing Xu², Cheng Xue², Zhiguo Mao²

Affiliations

¹ School of Medicine, Shanghai University, Shanghai, China.
² Division of Nephrology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic hereditary kidney disease, is the fourth leading cause of end-stage kidney disease worldwide. In recent years, significant progress has been made in delaying ADPKD progression with different kinds of chemical drugs, such as tolvaptan, rapamycin, and somatostatin. Meanwhile, numerous plant-derived compounds have been investigated for their beneficial effects on slowing ADPKD progression. Among them, saikosaponin-d, Ganoderma triterpenes, curcumin, ginkgolide B, steviol, resveratrol, Sparganum stoloniferum Buch.-Ham, Cordyceps sinensis, triptolide, quercitrin, naringin, cardamonin, gambogic acid, and olive leaf extract have been found to retard renal cyst development by inhibiting cell proliferation or promoting cell apoptosis in renal cyst-lining epithelial cells. Metformin, a synthesized compound derived from French lilac or goat's rue (Galega officinalis), has been proven to retard the progression of ADPKD. This review focuses on the roles and mechanisms of plant-derived compounds in treating ADPKD, which may constitute promising new therapeutics in the future.

Keywords: herbal medicine; mechanism; plant-derived compounds; polycystic kidney disease; treatment.

Publication types

Review

Grants and funding

The authors acknowledge the financial support from the National Natural Science Foundation of China (81770670 and 82070705); Medical innovation research project of Shanghai Science and Technology Innovation Plan (22Y11905500); Medical-enterprise integration innovation achievement transformation project (SHDC2022CRD024).